CY1112561T1 - Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης - Google Patents

Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης

Info

Publication number
CY1112561T1
CY1112561T1 CY20121100179T CY121100179T CY1112561T1 CY 1112561 T1 CY1112561 T1 CY 1112561T1 CY 20121100179 T CY20121100179 T CY 20121100179T CY 121100179 T CY121100179 T CY 121100179T CY 1112561 T1 CY1112561 T1 CY 1112561T1
Authority
CY
Cyprus
Prior art keywords
eye
vitreous
plasmin
reduce
color
Prior art date
Application number
CY20121100179T
Other languages
Greek (el)
English (en)
Inventor
Steve Pakola
Smet Marc De
Original Assignee
Thrombogenics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombogenics N.V. filed Critical Thrombogenics N.V.
Publication of CY1112561T1 publication Critical patent/CY1112561T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02005—Chondroitin AC lyase (4.2.2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02019—Chondroitin B lyase (4.2.2.19)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Insulating Materials (AREA)
CY20121100179T 2002-12-06 2012-02-21 Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης CY1112561T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228409.9A GB0228409D0 (en) 2002-12-06 2002-12-06 Pharmacological vitreolysis
EP03812818A EP1581254B1 (fr) 2002-12-06 2003-12-05 Vitreolyse pharmacologique en utilisant une plasmine raccourci

Publications (1)

Publication Number Publication Date
CY1112561T1 true CY1112561T1 (el) 2015-11-04

Family

ID=9949140

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100179T CY1112561T1 (el) 2002-12-06 2012-02-21 Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης
CY2013033C CY2013033I2 (el) 2002-12-06 2013-08-23 Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2013033C CY2013033I2 (el) 2002-12-06 2013-08-23 Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης

Country Status (25)

Country Link
US (11) US7547435B2 (fr)
EP (3) EP2327416B1 (fr)
JP (4) JP5426063B2 (fr)
CN (1) CN100577202C (fr)
AT (1) ATE534400T1 (fr)
AU (1) AU2003300821C1 (fr)
BE (1) BE2013C055I2 (fr)
BR (2) BRPI0310144A8 (fr)
CA (1) CA2508606C (fr)
CY (2) CY1112561T1 (fr)
DK (1) DK1581254T3 (fr)
ES (2) ES2377965T3 (fr)
FR (1) FR13C0052I2 (fr)
GB (1) GB0228409D0 (fr)
HK (1) HK1082419A1 (fr)
HU (1) HUS1300040I1 (fr)
IL (3) IL169008A (fr)
LU (1) LU92273I2 (fr)
MX (1) MXPA05006038A (fr)
NO (4) NO333837B1 (fr)
NZ (1) NZ541075A (fr)
PT (2) PT2327416T (fr)
SI (1) SI1581254T1 (fr)
WO (1) WO2004052228A2 (fr)
ZA (1) ZA200505193B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7152975B2 (en) * 2000-11-10 2006-12-26 Cooper Vision, Inc. Junctionless ophthalmic lenses and methods for making same
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
AU2005238464B2 (en) 2004-04-22 2011-01-27 Grifols Therapeutics Inc. Recombinantly modified plasmin
JP4796787B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007005856A1 (fr) * 2005-06-30 2007-01-11 Ista Pharmaceuticals, Inc. Utilisation de l'hyaluronidase en combinaison ave la plasmine pour l'induction du decollement posterieur du vitre
US8231869B2 (en) * 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
US20070134230A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
CA2651194A1 (fr) * 2006-05-04 2007-11-15 Fondation Ophthalmologique Aldolphe De Rothschild Methodes de traitement des maladies neovasculaires
HUE024916T2 (en) * 2007-11-29 2016-02-29 Grifols Therapeutics Inc Recombinantly modified plasmin
EP2249863A4 (fr) * 2008-01-22 2011-12-28 Omnio Healer Ab Méthode d'amélioration de la cicatrisation des plaies
US20110097421A1 (en) * 2008-03-31 2011-04-28 Bruno Gogly Method for the Cosmetic Treatment of Skin Ageing
US8617863B2 (en) * 2008-06-04 2013-12-31 Grifols Therapeutics Inc. Composition, method, and kit for preparing plasmin
PT2403865E (pt) 2009-03-03 2015-11-18 Grifols Therapeutics Inc Métodos de preparação de plasminogénio
US8858924B2 (en) * 2009-03-26 2014-10-14 Warsaw Orthopedic, Inc. Compositions and methods for treatment of hemorrhage
EP2451835A1 (fr) * 2009-07-10 2012-05-16 ThromboGenics N.V. Variantes du plasminogène et de la plasmine
EP2480249B1 (fr) 2009-08-28 2015-01-28 ThromboGenics N.V. Plasmine pour le traitement de defauts de filtration suite à la trabéculectomie
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
CN103384722B (zh) 2011-01-05 2016-11-16 斯路姆基因公司 纤溶酶原和纤溶酶变体
WO2012174243A1 (fr) * 2011-06-17 2012-12-20 Allergan, Inc. D-sérine dans le traitement des troubles du système visuel
KR20140064841A (ko) 2011-08-12 2014-05-28 쓰롬보제닉스 엔.브이. 플라스미노겐 변이체 및 플라스민 변이체
RU2484795C2 (ru) * 2011-08-18 2013-06-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ индукции задней отслойки стекловидного тела с помощью миниплазмина
EP2785739B1 (fr) 2011-12-01 2017-03-15 ThromboGenics N.V. Amélioration du résultat de la trabéculectomie
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
JP2015515487A (ja) 2012-04-24 2015-05-28 スロンボジェニックス エヌ．ブイ． 抗ｐｄｇｆ−ｃ抗体
US9730888B2 (en) 2013-03-14 2017-08-15 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
FR3034992A1 (fr) 2015-04-15 2016-10-21 Arcadophta Milieu plasmatique ex vivo autologue riche en plasmine et procede d'obtention
DK3395354T3 (da) * 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
CA3008691A1 (fr) 2015-12-18 2017-06-22 Talengen International Limited Procede pour prevenir ou traiter la retinopathie diabetique
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
RU2619991C1 (ru) * 2016-02-18 2017-05-22 Павел Владимирович Лыскин Способ лечения витреомакулярного тракционного синдрома
CA3013808A1 (fr) 2016-03-10 2017-09-14 Thrombogenics Nv Inhibition posterieure de la fibrose oculaire par antagonisation du facteur de croissance placentaire
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
TWI644682B (zh) 2016-12-15 2018-12-21 深圳瑞健生命科學硏究院有限公司 一種纖溶酶原在製備促進胰島細胞損傷修復的藥物上的用途
CN110506105B (zh) 2017-03-28 2023-03-24 森永乳业株式会社 新型双歧杆菌属细菌
RU2674926C1 (ru) * 2018-02-01 2018-12-13 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Способ оценки эффективности витреолизиса помутнений стекловидного тела
CN110361242B (zh) * 2019-08-14 2022-01-18 武汉赛维尔生物科技有限公司 一种用于眼球组织的固定液以及眼球组织制片的预处理方法
EP4041312A4 (fr) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658972A (en) * 1900-04-09 1900-10-02 Interchangeable Brake Beam Company Brake-beam.
US2624691A (en) 1946-04-22 1953-01-06 Parke Davis & Co Fibrinolysin derived from blood and methods of obtaining the same
DK98833C (da) 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
US3234106A (en) 1962-12-03 1966-02-08 Cutter Lab Soluble, purified profibrinolysin and fibrinolysin and method of producing same
US3950513A (en) 1965-12-03 1976-04-13 Novo Terapeutisk Laboratorium A/S Process of stabilizing therapeutically useful plasmin solutions
IT1194135B (it) 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US5288485A (en) 1989-08-31 1994-02-22 Kao Corporation Vasodilating agent
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5288489A (en) * 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
AU4661493A (en) 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5304118A (en) * 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5973779A (en) 1996-03-29 1999-10-26 Ansari; Rafat R. Fiber-optic imaging probe
US6207066B1 (en) 1996-07-23 2001-03-27 Nuvue Technologies, L.L.C. Method for purification of a blood component
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5722428A (en) 1996-10-29 1998-03-03 Washington University Method for producing a posterior vitreous detachment
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
BR9809558A (pt) 1997-05-22 2000-07-04 Advanced Corneal Systems Inc Uso de hialuronidase na fabricação de um preparado oftálmico para liquefazer o humor vìtreo no tratamento de perturbações do olho
EP1053330B1 (fr) 1998-02-04 2005-05-04 Thromb-X N.V. Identification, production et utilisation de derives de la staphylokinase avec immunogenecite et/ou clearance reduites
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6462071B1 (en) 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6585972B2 (en) 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US20040081643A1 (en) 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
AU1057901A (en) 1999-11-10 2001-06-06 Center For Advanced Science And Technology Incubation, Ltd. Method of preparing cell fraction containing hemangioblasts
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
ATE321069T1 (de) * 2000-05-12 2006-04-15 Vlaams Interuniv Inst Biotech Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
JP4047170B2 (ja) 2000-12-21 2008-02-13 トロム−イクス・ナムローゼ・フエンノートシャップ 酵母発現ベクターおよび酵母細胞における発現による組換えタンパク質の製造方法
US20020139378A1 (en) * 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
FI20011132A0 (fi) 2001-05-30 2001-05-30 Innovationsagentur Markkeri hematopoieettisten kantasolujen tunnistamiseen
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
US20040235115A1 (en) * 2002-11-18 2004-11-25 Reed Guy L. Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
JP5451533B2 (ja) 2014-03-26
NO343759B1 (no) 2019-06-03
EP1581254A4 (fr) 2007-03-28
CN1738641A (zh) 2006-02-22
CY2013033I1 (el) 2015-11-04
NO333837B1 (no) 2013-09-30
US9770494B2 (en) 2017-09-26
LU92273I2 (fr) 2013-10-29
EP2327416A1 (fr) 2011-06-01
AU2003300821B2 (en) 2009-07-09
SI1581254T1 (sl) 2012-05-31
JP2013241448A (ja) 2013-12-05
US7867489B2 (en) 2011-01-11
LU92273I9 (fr) 2019-01-15
NO2013016I2 (no) 2017-06-28
CN100577202C (zh) 2010-01-06
US8383105B2 (en) 2013-02-26
EP2327415B1 (fr) 2017-10-18
IL213838A0 (en) 2011-07-31
AU2003300821A1 (en) 2004-06-30
WO2004052228A2 (fr) 2004-06-24
US7914783B2 (en) 2011-03-29
GB0228409D0 (en) 2003-01-08
AU2003300821C1 (en) 2012-03-22
CA2508606A1 (fr) 2004-06-24
US20080095753A1 (en) 2008-04-24
PT2327416T (pt) 2019-07-04
NO20121169A1 (no) 2012-10-12
BE2013C055I2 (fr) 2023-03-07
IL202851A (en) 2015-04-30
WO2004052228A3 (fr) 2004-10-07
BR0317033A (pt) 2005-10-25
EP1581254A2 (fr) 2005-10-05
FR13C0052I2 (fr) 2014-11-21
US20110171190A1 (en) 2011-07-14
CA2508606C (fr) 2015-07-28
NO20121170A1 (no) 2012-10-12
JP2015131842A (ja) 2015-07-23
NO20052988D0 (no) 2005-06-17
DK1581254T3 (da) 2012-02-27
US20050118158A1 (en) 2005-06-02
MXPA05006038A (es) 2006-03-08
US7547435B2 (en) 2009-06-16
US20150064161A1 (en) 2015-03-05
US20130195887A1 (en) 2013-08-01
HK1082419A1 (en) 2006-06-09
US7803368B2 (en) 2010-09-28
US20110300123A1 (en) 2011-12-08
US8834869B2 (en) 2014-09-16
BRPI0310144A8 (pt) 2018-04-24
ZA200505193B (en) 2007-08-29
JP2010222369A (ja) 2010-10-07
US20080050356A1 (en) 2008-02-28
PT1581254E (pt) 2012-02-06
CY2013033I2 (el) 2015-11-04
US8460655B2 (en) 2013-06-11
ES2731625T3 (es) 2019-11-18
EP2327416B1 (fr) 2019-05-01
JP2006518708A (ja) 2006-08-17
JP5426063B2 (ja) 2014-02-26
EP2327415A1 (fr) 2011-06-01
FR13C0052I1 (fr) 2013-04-10
EP1581254B1 (fr) 2011-11-23
HUS1300040I1 (hu) 2013-08-15
IL169008A (en) 2011-08-31
ES2377965T3 (es) 2012-04-03
NO2013016I1 (no) 2013-11-19
JP5739487B2 (ja) 2015-06-24
NO20052988L (no) 2005-09-05
IL202851A0 (en) 2011-07-31
ATE534400T1 (de) 2011-12-15
US20090074739A1 (en) 2009-03-19
US20130302304A1 (en) 2013-11-14
NZ541075A (en) 2008-02-29
US9186394B2 (en) 2015-11-17
US20130202613A1 (en) 2013-08-08
JP5996026B2 (ja) 2016-09-21
US20090081187A1 (en) 2009-03-26
US8747842B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
CY1112561T1 (el) Φαρμοκολογικη λυση του υαλοειδους, με τη χρηση κολουρης πλασμινης
HRP20050845A2 (en) Prostaglandin analogs as ep4 receptor antagonists
EA200700109A1 (ru) Способы лечения офтальмологических состояний (варианты)
DE69521620T2 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE60119534D1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
BR0007595A (pt) 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina
ATE295829T1 (de) Verwendung von biologisch aktivem glas zum schneiden von biologisch aktivem glas
DE69924254D1 (de) Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks
NO990522D0 (no) Anvendelse av <beta>-ark mimetika som protease- og kinaseinhibatorer av transkripsjonsfaktorer
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
BR0210013A (pt) Gel oftálmico de pirenzepina
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
PE20020144A1 (es) Derivados de pleuromutilinas como agentes antibacterianos
ATE288274T1 (de) Ophatlmologische zusammenssetzung
DE60317098D1 (de) Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten
CY1106409T1 (el) Παραγωγα κινολινης
PT1169026E (pt) Utilizacao de activadores de ap-1 no tratamento do glaucoma e da hipertensao ocular